Consensus NewAmsterdam Pharma Company N.V. Nasdaq

Stocks

NAMS

NL00150012L7

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-09-18 EDT			5-day change	1st Jan Change
22.49 ^USD	+2.55%		-1.36%	-35.89%

08-26	NewAmsterdam Pharma Presents Data From Obicetrapib Development Program At European Society Of Cardiology Congress 2026	CI
08-14	Newamsterdam Pharma Company N.V. Announces Executive Changes	CI

ca7f53564b.Cc8u2d-wxPlhw425ctpYQV-egCARYj2m5uNCz_m_UbE.OZkc65rktoowjruNCIlodznNuWFkI1GUuaEsnsuIKclxtVe9kOqAvTLytQ~88050b1ad98a82609bd5b219b1980ce2

Analysts' recommendations: NewAmsterdam Pharma Company N.V.

08-06	RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating	MT
07-21	BMO Capital Initiates NewAmsterdam Pharma at Outperform With $58 Price Target	MT
06-30	NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says	MT
06-30	RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk	MT
03-19	Truist Initiates NewAmsterdam Pharma at Buy With $57 Price Target	MT
01-21	RBC Raises Price Target on NewAmsterdam Pharma to $47 From $44, Keeps Outperform, Speculative Risk	MT
11-06	RBC Raises Price Target on NewAmsterdam Pharma to $44 From $39, Keeps Outperform, Speculative Risk	MT
25-08-25	Wells Fargo Initiates Coverage on NewAmsterdam Pharma With Overweight Rating, $45 Price Target	MT
25-08-07	RBC Lifts Price Target on NewAmsterdam Pharma to $39 From $38, Keeps Outperform, Speculative Risk	MT
25-07-17	Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target	MT
25-06-17	Citigroup Initiates NewAmsterdam Pharma at Buy With $42 Price Target	MT
25-06-10	Stifel Nicolaus Initiates Coverage on NewAmsterdam Pharma With Buy Rating, $44 Price Target	MT
25-06-04	Cantor Fitzgerald Initiates NewAmsterdam Pharma Overweight With $42 Price Target	MT
24-12-30	HC Wainwright Initiates NewAmsterdam Pharma at Buy With $48 Price Target	MT
24-08-28	Needham Initiates NewAmsterdam Pharma at Buy With $36 Price Target	MT
24-05-15	TD Cowen Starts NewAmsterdam Pharma With Buy Rating	MT
24-03-14	Scotiabank Starts NewAmsterdam Pharma With Sector Outperform Rating, $35 Price Target	MT
24-02-29	RBC Raises Price Target on NewAmsterdam Pharma to $31 From $25, Keeps Outperform, Speculative Risk	MT
24-01-18	Guggenheim Starts NewAmsterdam Pharma With Buy Rating, $30 Price Target	MT
23-10-30	RBC Initiates NewAmsterdam Pharma at Outperform With Speculative Risk Qualifier, $25 Price Target	MT
23-04-03	Credit Suisse Lifts NewAmsterdam Pharma's Price Target to $22 From $21, Keeps Outperform Rating	MT
23-01-06	Credit Suisse Starts NewAmsterdam Pharma at Outperform With $21 Price Target	MT
22-12-20	SVB Securities Initiates Coverage on NewAmsterdam Pharma With Outperform Rating, $19 Price Target	MT
22-12-20	SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target	MT
22-12-19	William Blair Starts NewAmsterdam Pharma at Outperform	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+16.92%
	ARGENX SE					+17.96%
	INSMED INCORPORATED					+66.29%
	WUXI BIOLOGICS (CAYMAN) INC.					+15.47%
	BIONTECH SE					+23.62%
	GENMAB A/S					+8.57%
	PHARMAESSENTIA CORPORATION					+18.41%
	EXELIXIS, INC.					-8.01%
	SUMMIT THERAPEUTICS INC.					+62.99%
	Average					+24.69%
	Weighted average by Cap.					+22.84%